|1.||Liu, Tong: 2 articles (12/2015 - 04/2015)|
|2.||Peng, Xiao-Yan: 1 article (12/2015)|
|3.||Wang, Xue-Long: 1 article (12/2015)|
|4.||Chen, Li-Hua: 1 article (12/2015)|
|5.||Cao, Lei-Fang: 1 article (12/2015)|
|6.||Luo, Wei-Feng: 1 article (12/2015)|
|7.||Huang, Ya: 1 article (12/2015)|
|8.||Jiang, Xinghong: 1 article (04/2015)|
|9.||Zhou, Youlang: 1 article (04/2015)|
|10.||Wang, Shusheng: 1 article (04/2015)|
02/01/1997 - "The stimulatory effect of butoxamine on the gastric mucosal potential difference and intramucosal mucus level correlated positively with its anti-ulcer action. "
02/01/1997 - "We suggest that the anti-ulcer effect of butoxamine was in part a result of strengthening of the mucosal barrier but that this was not effected by modification of acid or pepsin secretions in the stomach. "
02/01/1997 - "Oral administration of butoxamine but not metoprolol significantly attenuated gastric mucosal damage in the three types of ulcer model. "
12/12/1996 - "In addition, oral administration of propranolol and butoxamine increased the mucosal prostaglandin E2 level, which could partially contribute to their anti-ulcer effects."
02/01/1997 - "Oral administration of butoxamine also significantly increased the mucosal PGE2 level in the three types of ulcer model but this drug was only effective in the indomethacin ulcer model after intraperitoneal injection. "
|2.||Cardiac Arrhythmias (Arrythmia)
|3.||Airway Obstruction (Choking)
09/01/1991 - "Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission. "
10/01/1986 - "A comparative study of the antitremor activity of beta-adrenoceptor antagonists against this tremor-model showed that butoxamine (beta 2-antagonist) and propranolol (nonselective antagonist) were able to afford a rapid and powerful protection, whereas a weaker and delayed effect was observed in rats treated with the beta 1-antagonist, acebutolol. "
03/11/1986 - "The dose of isoprenaline (0.1 mg/kg) that markedly reduced the effect of butoxamine did not alter the effect of acebutolol, suggesting that antagonism of peripheral beta 1-adrenoceptor was not responsible for the antitremor action of acebutolol and that blockade of peripheral beta 2-receptors is involved to a great extent in the inhibition of tremors by butoxamine. "
03/11/1986 - "Specific beta 1- and beta 2-adrenoceptor antagonists, acebutolol and butoxamine respectively were used to investigate the involvement of blockade of these receptors in the inhibition of harmaline-induced tremors. "
10/01/1986 - "It was inferred that beta 2-receptor modulated the tremorogenic activity of tremorine, and that inhibition by propranolol or butoxamine of this subtype beta-adrenoceptor resulted in rapid and powerful suppression of tremors, and that the antiadrenergic activity of acebutolol was unlikely to have a role in its antitremor effect."
03/01/1993 - "To investigate what property of beta-blockers plays the main role in suppressing tremor, we employed five beta-blockers (propranolol, atenolol, butoxamine, pindolol, and arotinolol). "
09/01/2011 - "Therefore, we assessed the effects of β2AR antagonist butoxamine on the protection of oxygen treatment against zymosan-induced generalized inflammation in mice. "
09/01/2011 - "β2-adrenergic receptor antagonist butoxamine partly abolishes the protection of 100% oxygen treatment against zymosan-induced generalized inflammation in mice."
01/01/1992 - "Propranolol, a nonselective beta-adrenergic receptor antagonist reduced and butoxamine, a beta 2-antagonist, significantly reduced the urethral inflammation. "
|7.||Adrenergic Antagonists (Antiadrenergic Agents)
|3.||Drug Therapy (Chemotherapy)